Deals In Depth: October 2018
Executive Summary
J&J and Lilly each penned $3.7 billion RNAi alliances, with Arrowhead and Dicerna, respectively. Novartis made another move into radiopharmaceuticals with the $1.9 billion buy of Endocyte. Over $1 billion was raised through biopharma IPOs.